Diagnosing HER2 receptor expression is crucial to identify patients expected to benefit from treatment, as well as to avoid unnecessary cost and potential risk of serious adverse effects of treatment for patients with HER2-negative tumours. This evidence concerns the gene ERBB2 and neoplasm.